AUTHORS
Gvantsa Pantsulaia, MS, Moah Sohn2, Xueying Cheng3, Nicole Hirsh4, Ivan Odak, PhD5, Samir Parekh, MD6, Joshua D. Brody, MD7
AFFILIATIONS
1 Icahn School of Medicine, New York, New York, United States, Wright State University Boonshoft School of Medicine, Dayton, Ohio, United States
2 Icahn School of Medicine, New York, New York, United States
3 Icahn School of Medicine, New York, New York, United States
4 Icahn School of Medicine, New York, New York, United States
5 Icahn School of Medicine, New York, New York, United States
6 Icahn School of Medicine, New York, New York, United States
7 Icahn School of Medicine, New York, New York, United States
ABSTRACT
Background:
Bispecific antibodies (BsAbs) have transformed T-cell-redirecting therapy for hematologic malignancies. However, developing each new BsAb remains a resource- and time-intensive trial-and-error process requiring the selection and optimization of specific antigen-binding combinations. Tumor antigen heterogeneity and antigen loss further limit the durability of single-target therapies. Therefore, a modular approach that rapidly converts existing monoclonal antibodies into functional multispecific agents could accelerate target screening and therapeutic development. We developed FlexiBiTE, a flexible BsAb platform designed to mix and match existing antibodies and redirect immune activity against diverse tumor targets. Here, we investigate whether FlexiBiTE could accelerate bispecific antibody development while maintaining therapeutic efficacy and providing broader utility beyond T-cell redirection.
Methods:
Double Flexi was engineered to selectively recognize any two of the rat IgG1, IgG2a, and IgG2b isotypes, enabling rapid assembly of bispecific molecules from off-the-shelf monoclonal antibodies. CD3-containing FlexiBiTE molecules and an albumin-fused variant were generated for therapeutic evaluation. Incubation with selected monoclonal antibodies generated target-specific bispecific molecules, which were evaluated for T-cell redirection, immune receptor modulation, targeted lipid nanoparticle (LNP) delivery, and antitumor activity using primary mouse T-cell coculture assays, receptor-signaling assays, endogenous B-cell depletion, and the EZB-GFP-luc lymphoma model.
Results:
FlexiBiTE rapidly assembled functional bispecific molecules from commercially available monoclonal antibodies, eliminating the need to re-engineer target-binding antibodies. The same adaptor scaffold was readily redirected toward multiple hematologic and solid tumor antigens, including CD20, BAFF-R, PD-L1, EpCAM, and CD138. When configured as T-cell engagers, simply exchanging the targeting antibody preserved potent antigen-dependent tumor killing and T-cell expansion across lymphoma, leukemia, myeloma, and breast cancer models.
The platform remained functional in vivo. CD20-directed FlexiBiTE efficiently depleted circulating and splenic B cells, demonstrating stable assembly and biological activity following systemic administration. Extending these findings, in an aggressive EZB-GFP-luc lymphoma model, CD20-directed FlexiBiTE achieved durable tumor control, while an albumin-fused FlexiBiTE further improved therapeutic efficacy, resulting in complete long-term survival.
Beyond T-cell redirection, FlexiBiTE enabled programmable immune receptor modulation and targeted molecular delivery. Engagement of the costimulatory receptors CD27, CD28, 4-1BB, and OX40 enhanced T-cell proliferation and expansion. FlexiBiTE also assembled functional receptor complexes: IFNγR1/IFNγR2 co-engagement induced ligand-independent STAT1 signaling, whereas CD122/CD132 co-engagement promoted T-cell expansion. In a separate application, FlexiBiTE redirected PEGylated GFP mRNA-loaded lipid nanoparticles to selected cell populations using interchangeable targeting antibodies, enabling receptor-specific nanoparticle binding and functional mRNA expression across multiple receptors and cellular contexts.
Conclusions:
FlexiBiTE is a modular and highly adaptable platform that converts existing monoclonal antibodies into functional bispecific therapeutics without target-specific protein engineering. A single adaptable scaffold supports interchangeable T-cell engagers, immune receptor modulation, and targeted molecular delivery while demonstrating durable in vivo efficacy. FlexiBiTE addresses a critical limitation in bispecific antibody development and breaks through the long-standing bottleneck in the field, offering a powerful and scalable route for rapid discovery, testing, and optimization of next-generation immunotherapies for lymphoma and other hematologic malignancies.
DISCLOSURES
Gvantsa Pantsulaia, MS: No relevant conflicts of interest to declare.